PressMarch 11, 2025 Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
PressMarch 11, 2025 MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
PressMarch 11, 2025 Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
PressMarch 11, 2025 Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
PressMarch 11, 2025 PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
PressMarch 11, 2025 Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
PressMarch 11, 2025 Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order
PressMarch 8, 2025 atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
PressFebruary 14, 2025 Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
PressFebruary 12, 2025 Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
PressFebruary 12, 2025 Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
PressFebruary 7, 2025 Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
PressFebruary 7, 2025 Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
PressFebruary 7, 2025 Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
PressJanuary 31, 2025 MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
PressJanuary 31, 2025 Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
PressJanuary 31, 2025 Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
